Dual inhibitors are under investigation for the treatment of diabetes and expected to yield greater glucose-lowering and pleiotropic benefits compared with selective SGLT2 inhibitors (Zambrowicz et al., 2012; Rosenstock et al., 2015). This evidence concerns the gene SLC5A2 and diabetes mellitus.